Last reviewed · How we verify
Lomustine Chemotherapy
Lomustine is a nitrosourea alkylating agent that cross-links DNA strands, preventing cancer cell replication and inducing cell death.
Lomustine is a nitrosourea alkylating agent that cross-links DNA strands, preventing cancer cell replication and inducing cell death. Used for Brain tumors (glioblastoma, high-grade gliomas), Hodgkin lymphoma, Non-Hodgkin lymphoma.
At a glance
| Generic name | Lomustine Chemotherapy |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Nitrosourea alkylating agent |
| Target | DNA (non-selective alkylating agent) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Lomustine forms covalent bonds with DNA bases, creating interstrand and intrastrand cross-links that block DNA replication and transcription. This leads to apoptosis in rapidly dividing cancer cells. As a lipophilic compound, it crosses the blood-brain barrier effectively, making it particularly useful for CNS malignancies.
Approved indications
- Brain tumors (glioblastoma, high-grade gliomas)
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
- Melanoma
Common side effects
- Myelosuppression (thrombocytopenia, leukopenia)
- Nausea and vomiting
- Anemia
- Pulmonary fibrosis (delayed, cumulative)
- Secondary malignancy
- Hepatotoxicity
- Renal toxicity
Key clinical trials
- Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas
- Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma (PHASE2)
- Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma (PHASE3)
- A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas). (PHASE3)
- A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery (PHASE3)
- gliomasPCV Only in 1p/19q Codeleted Anaplastic Gliomas (PHASE3)
- Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma (PHASE3)
- Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |